EU GMP Training: Essentials of EudraLex Volume 4 Part I

Opens with a self-check: how well do you know the EU GMP Guide, what is GMP for, and who decides at your site that a batch may be sold in the EU? Then three cases. In March 2026, Croatia's medicines authority, inspecting for the EU, found ten critical and twenty-one major deficiencies at Swiss Parenterals, a sterile injectables maker in India, including deviations nobody had reported. Falsified pens labelled as Ozempic reached EU and UK wholesalers. And children's cough syrups contaminated with toxic glycols. Explains what good manufacturing practice is in one picture: quality built into every unit through defined processes, trained people and true records. Introduces JKL Pharma Ltd, with sites in Mumbai and Singapore and JKL Pharma Europe in Dublin, plus a contract laboratory in Paris and a biotech in Frankfurt. Outlines the fourteen modules, exercises and exam, and closes with a recap.

What you will be able to do

• Explain what EU good manufacturing practice is for
• Recognise the GMP failures behind three recent cases
• Identify who decides that a batch may be sold in the EU

Why it matters

For a site supplying the EU, inspection findings decide whether its batches can be released at all.

Practice: Practice: Welcome: why EU GMP matters · 3 questions

Starts with JKL Pharma's Mumbai site, told an EU authority will inspect it, asking which rules the inspector will use. Builds the framework from the top: Directive 2001/83/EC requiring manufacturing and import authorisations, Commission Directive (EU) 2017/1572 on GMP principles, and the GMP Guide in EudraLex Volume 4 with its parts and annexes. Explains what this means for sites outside the EU: Mumbai and Singapore make the batches, and JKL Pharma Europe in Dublin tests and certifies them under its authorisation. Covers EU inspections, GMP certificates, site master files, the PIC/S GMP Guide, a generics maker in London and a tablet maker in Hong Kong. Shows JKL's EU regulatory register, owned by the quality head in Dublin, and the revisions to watch, from Annex 1 in 2022 to Annex 19, Chapter 4 and Annex 11. Closes with a recap: know what binds you, and in what order.

What you will be able to do

• Explain how EU law, the GMP Guide and procedures fit together
• Describe how authorisations, inspections and certificates work
• Keep a regulatory register of texts, certificates and revisions

Why it matters

Every inspector checks against their own framework; knowing the EU order tells you what binds and what explains it.

Practice: Practice: The EU GMP framework · 3 questions

Returns to the case from Module 1, whose first critical deficiency was a quality system that did not cover sterile manufacture, with weak deviation management and risk decisions not put into practice. Reads Chapter 1's objective: medicines fit for their intended use, meeting their marketing authorisation and not putting patients at risk, with senior management responsible and staff and suppliers taking part. Explains how quality control sits inside GMP, which sits inside quality management, and how the system is documented, resourced and monitored. Covers quality risk management based on science, linked to the patient, with effort matched to risk, such as a short documented check for a minor label smudge at JKL. Shows GMP applying from technology transfer, quarterly management review and JKL's one-page quality system map. Compares a Paris vaccine maker with a small Frankfurt contract packer, and closes with a recap.

What you will be able to do

• Explain the quality objective set out in EU GMP Chapter 1
• Describe how quality control, GMP and quality management relate
• Apply quality risk management with effort matched to the risk

Why it matters

Inspectors judge a quality system by what it does, not by what the manual says; this shows them what to look for.

Practice: Practice: The pharmaceutical quality system · 3 questions

Opens at JKL Pharma's Mumbai site, where every batch of metformin 500 milligram tablets met its dissolution specification, but the yearly average fell month after month. Reads paragraph 1.10 on regular reviews of all authorised products, including those made only for export, to check consistency, specifications and trends. Shows how Mumbai prepares the review and JKL Pharma Europe evaluates it under their technical agreement, then opens the 2025 review, with a new binder supplier approved in March just before the drift began. Covers change management, evaluated before approval and checked afterwards, deviations with root cause analysis matched to risk and justified human error, and a CAPA whose effectiveness check runs for six months. Ends with management review, one slide per product, a Paris cream maker's grouped reviews, a practice exercise writing a review summary, and a recap.

What you will be able to do

• Write a product quality review that highlights trends
• Evaluate changes before approval and check their effect afterwards
• Set an effectiveness check for a corrective and preventive action

Why it matters

A slow drift hides inside results that all meet specification; the product quality review is where you see it.

Practice: Practice: Product quality review and improvement · 3 questions

Returns to the April 2026 case, where training records existed but aseptic technique, operator behaviour, gowning and hygiene fell short of the EU's sterile annex. Reads Chapter 2's principle: correct manufacture relies on people, with enough qualified staff whose responsibilities are understood and recorded. Covers organisation charts and job descriptions, the independent heads of production and quality control, and at least one Qualified Person who certifies batches and delegates only to another Q-P. Explains initial and continuing training with its effectiveness assessed, using JKL's training matrix for each site, and qualifications on file for visitors and consultants before they start. Covers hygiene rules for every person, every time, with a Paris vaccine maker's clean areas and a Tokyo night shift with new staff. Closes with a recap: training is judged by behaviour, not by signatures.

What you will be able to do

• Describe the key personnel EU GMP Chapter 2 requires
• Check that training is effective, not just recorded
• Apply personal hygiene rules to staff, visitors and consultants

Why it matters

A training record shows training happened; whether it worked is shown in what people do when nobody is watching.

Practice: Practice: Personnel: training and hygiene · 3 questions

Starts with the April 2026 case's findings on buildings: missing barrier systems, poor material routes and cross-contamination risks in a beta-lactam unit. Reads Chapter 3's principle: premises and equipment located, designed, built and maintained to minimise errors and allow effective cleaning, and Article 8 of the Directive. Covers the general rules in paragraphs 3.1 to 3.5, such as JKL's Mumbai canteen reached by an outside walkway, and paragraph 3.6 on dedicated facilities, applied to JKL's beta-lactam antibiotics. Then production, storage and laboratory areas, with dusty powders at a Sydney tablet maker. Explains equipment qualified before use, calibrated at defined intervals, labelled with its status, and defective items removed or marked, with JKL's room status board in Mumbai. Closes with a recap: good design makes the right way the easy way.

What you will be able to do

• Check that premises are designed to prevent mix-ups and contamination
• Explain when EU GMP requires dedicated facilities
• Confirm that equipment is qualified, calibrated and status-labelled

Why it matters

No amount of training can make up for a layout that brings people, materials and products together in the wrong places.

Practice: Practice: Premises and equipment · 3 questions

Opens with the April 2026 case, where documents were not supplied promptly and inspectors doubted that records were attributable and made at the time, a critical deficiency. Reads Chapter 4's principle: documents on paper, electronic or photographic media, fully defined in the quality system, as instructions and records, with the site master file. Covers good documentation practice: legible entries made at the time and corrected openly with a signature, date and reason. Shows a granulation step in a metformin batch record at JKL's Mumbai site and what paragraph 4.20 says it should contain, then retention periods. Explains Annex 11: validated systems, controlled access, reviewed audit trails and linked electronic signatures, with a Sydney packaging site using paper and screens. Notes the 2025 drafts of Chapter 4 and Annex 11. Ends with a practice exercise reviewing a batch record page and an audit trail, and a recap.

What you will be able to do

• Apply good documentation practice to batch record entries
• Explain what EU GMP asks of computerised systems and audit trails
• Check that records are kept for the required retention period

Why it matters

When an inspector cannot trust the records, they cannot trust anything the records claim.

Practice: Practice: Documentation and data integrity · 3 questions

Returns to the cough syrups of 2022 and 2023, contaminated with diethylene and ethylene glycol and linked by the WHO to more than three hundred deaths, and its call to qualify suppliers and test on receipt. Reads Chapter 5's principle and general rules: written procedures, incoming checks, quarantine until release, clear labels and reconciled yields. Covers cross-contamination controlled with quality risk management, technical and organisational measures and periodic review, then process validation. Explains supplier approval and supervision by risk, traced and audited active substance supply chains, and at least an identity test on every batch received. Shows an extract from JKL's Mumbai supplier file, with the metformin active substance maker audited in 2025, and links back to the binder supplier approved in March. Adds a Dublin cream maker with dozens of excipients and closes with a recap: trust your supplier, and still check every delivery.

What you will be able to do

• Apply incoming checks and quarantine to starting materials
• Approve and supervise suppliers according to risk
• Explain how EU GMP controls cross-contamination in production

Why it matters

A medicine is only as good as its materials; checking every delivery stops a toxic ingredient at the door.

Practice: Practice: Materials, suppliers and cross-contamination · 3 questions

Starts on JKL Pharma's Mumbai blister line, where a checker found a roll of 1,000 milligram foil left from the previous batch during set-up for 500 milligram tablets. Covers dispensing by designated people with independent, recorded checks, made at JKL by scanning labels and comparing balance printouts. Explains processing and paragraphs 5.40 to 5.44 on packaging materials, with printed foils and cartons kept in a locked cage and logged against each batch. Shows JKL's line clearance checklist built from paragraph 5.50, checks of printing and devices, and reconciliation of every printed item before release. Follows batches to Dublin for testing and certification. Covers rejected, recovered and returned products, with returned refrigerated packs at a Paris injectables maker, and reporting supply constraints in good time. Closes with a recap: account for every label, every time.

What you will be able to do

• Run a packaging line clearance against a checklist
• Reconcile printed packaging materials before release
• Apply EU GMP rules to rejected and returned products

Why it matters

One stray label in the wrong pack tells a patient the wrong medicine or strength; line clearance is the last barrier.

Practice: Practice: Processing, packaging and returns · 3 questions

Opens with the April 2026 case, where inadequate out of specification investigations were a critical deficiency and quality control a major one. Reads Chapter 6's principle: quality control covers sampling, specifications and testing, is independent of production and takes part in every quality decision. Covers representative sampling, validated or verified methods and complete records, then how JKL's Singapore laboratory handled a real out of specification result, including out of trend results. Explains the ongoing stability programme through the shelf life, with an inhaler maker in London trending delivered dose, and method transfer under protocol, as JKL did for EU testing in Dublin using methods validated in Mumbai. Covers reference and retention samples under Annex 19, revised in June 2026, and a Paris contract laboratory. Closes with a recap: a failed result is a question that must be answered.

What you will be able to do

• Investigate an out of specification result before any retest
• Explain what an ongoing stability programme must show
• Transfer an analytical method under a written protocol

Why it matters

Repeating a test until it meets the limit hides the answer; a proper investigation shows whether the batch is defective.

Practice: Practice: Quality control · 3 questions

Starts with JKL Pharma's audit of its contract laboratory in Paris, which had sent one microbial test to a second laboratory nobody at JKL had assessed. Reads Chapter 7's principle: outsourced activities defined, agreed and controlled through a written contract setting out each party's duties, with the Qualified Person's responsibility clear, and Article 12 of the Directive. Explains the giver's duties to assess, inform, monitor and review, and the acceptor's duty never to subcontract without approval, as paragraph 7.11 says. Shows JKL's technical agreements between Mumbai and Dublin, and between Dublin and the Paris laboratory, with audit rights and record access. Covers Chapter 9 self-inspections: a programme, independent and detailed, recorded with actions, and JKL's self-inspection finding against its own oversight. Adds a Tokyo generics maker with a small team, a practice exercise and a recap.

What you will be able to do

• Write a technical agreement that sets out each party's GMP duties
• Monitor a contract acceptor, including any subcontracting
• Plan independent self-inspections and record their actions

Why it matters

You can outsource the work, but not the responsibility; a clear agreement and real oversight keep you in control.

Practice: Practice: Outsourcing and self-inspection · 3 questions

Opens with the falsified pens labelled as Ozempic found at EU and UK wholesalers in October 2023, with copied batch and serial numbers that showed as inactive when scanned. Explains why a report about an unusual pack may be a falsified product, and why Chapter 8 asks companies to check. Reads the principle: a system to record, assess, investigate and review complaints and defects, and to recall promptly, using quality risk management and informing authorities. Covers complaints assessed by trained people independent of sales, investigations of the defect, its extent, risk and root cause, and timely, proportionate decisions. Shows JKL's Dublin quality team working through one report across several markets. Explains recalls in paragraphs 8.20 to 8.30, with a Paris maker's defect in an expired batch and a Frankfurt mock recall. Ends with a practice exercise on ceftriaxone vials and a recap.

What you will be able to do

• Assess a complaint, always considering falsification
• Investigate a quality defect for its extent, risk and root cause
• Plan and test recall arrangements before they are needed

Why it matters

A complaint can be the first sign of a serious defect; the speed of your response can decide whether patients are harmed.

Practice: Practice: Complaints, defects and recalls · 3 questions

Returns to the April 2026 statements, which mean Qualified Persons cannot certify a non-compliant site's batches except, for a critical medicine, under strict conditions with authority agreement, and where repeated testing alone is not enough. Reads Annex 16's general principles: the marketing authorisation holder's lifetime responsibility and the Qualified Person's for each batch. Covers certification in a register before release, and paragraph 1.5 on products made outside the EU, relying on a documented, audited supply chain and testing in the EU. Shows how JKL Pharma Europe's Qualified Person in Dublin certifies metformin batch 2611. Then a map of the annexes, from the contamination control strategy in Annex 1 for JKL's Singapore site to Annex 19 revised in 2026, Annex 21 on importation, and safety features on packs printed in Mumbai. Closes with a recap: a signature is only as strong as its evidence.

What you will be able to do

• Explain what a Qualified Person checks before certifying a batch
• Describe the extra steps for batches made outside the EU
• Identify the EU GMP annexes that apply to your site

Why it matters

A Qualified Person's signature rests on the whole supply chain; knowing what it covers shows what your site must provide.

Practice: Practice: QP certification and the annexes · 3 questions

Opens with a question: if the inspector arrived on Monday, which three records would you check this weekend? Follows an EU inspection of JKL Pharma's Mumbai site, whose certificate is nearly three years old, in scope for metformin tablets and paracetamol oral solution. Takes six steps: preparing by checking the EU register, the site master file and product quality reviews, the floor, the records, the findings, the response and the outcome. Shows how the team handled the inspector's questions, what she found, and the response to the major finding by fixing causes. Ends with the authority issuing a new GMP certificate, public in EudraGMDP. Contrasts a Sydney tablet maker rewriting records the week before an inspection. Gives a six-step road map, a short checklist, the key takeaways and the final exam, with 60% or more for the Certificate of Competence.

What you will be able to do

• Prepare a site's evidence for an EU GMP inspection
• Respond to inspection findings by fixing their root causes
• Use a six-step road map to apply EU GMP at your own site

Why it matters

Inspections reward systems that work every day; seeing one from start to finish shows how to prepare without staging a show.

Practice: Practice: Putting it together: an EU inspection · 3 questions